PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
80.96
+1.98 (2.51%)
At close: Jun 22, 2026, 4:00 PM EDT
80.90
-0.06 (-0.07%)
After-hours: Jun 22, 2026, 6:05 PM EDT

PTC Therapeutics Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, PTC Therapeutics stock has a consensus rating of "Buy" and an average price target of $93.93. The average 1-year stock price forecast is 16.02% higher than the current stock price, while the lowest is $65 (-19.71%) and the highest is $124 (+53.16%).

Price Target: $93.93 (+16.02%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$65$93.93$92.5$124
Change-19.71%+16.02%+14.25%+53.16%

Analyst Ratings

The average analyst rating for PTC Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy765567
Buy333444
Hold445532
Sell000000
Strong Sell111111
Total151414151414

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Citi
Citi
Buy
Upgrades
$75$108
BuyUpgrades$75$108+33.40%Jun 9, 2026
Barclays
Barclays
Buy
Reiterates
$120
BuyReiterates$120+48.22%May 28, 2026
Jefferies
Jefferies
Buy
Upgrades
$76$85
BuyUpgrades$76$85+4.99%May 27, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aMay 15, 2026
J.P. Morgan
J.P. Morgan
Buy
Maintains
$80$89
BuyMaintains$80$89+9.93%May 11, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.17B
from 1.73B
Decreased by -32.21%
Revenue Next Year
1.31B
from 1.17B
Increased by 11.86%
EPS This Year
1.31
from 7.62
Decreased by -82.77%
EPS Next Year
2.78
from 1.31
Increased by 111.93%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
538.59M698.80M937.82M806.78M1.73B1.17B
Revenue Growth
41.45%29.75%34.20%-13.97%114.51%-32.21%
Gross Profit
-34.42M2.63M205.77M214.90M1.23B1.17B
Gross Margin
-6.39%0.38%21.94%26.64%70.98%100.00%
Operating Income
-374.94M-439.93M-349.40M-146.75M856.51M288.44M
Net Income
-523.90M-559.02M-626.60M-363.30M682.64M65.46M
EPS
----7.621.31
EPS Growth
------82.77%
Forward PE
-----61.64
Free Cash Flow
-214.16M-313.75M-31.73M-80.23M211.76M81.00M
No. Analysts
-----13
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.3B
Avg1.2B
Low1.1B

Revenue Growth

Revenue Growth202620272028
High
-25.1%
Avg
-32.2%
Low
-37.6%

EPS Forecast

EPS202620272028
High1.71
Avg1.31
Low0.85

EPS Growth

EPS Growth202620272028
High
-77.6%
Avg
-82.8%
Low
-88.8%